Previous close | 26.52 |
Open | 26.55 |
Bid | 27.45 x 100 |
Ask | 27.59 x 100 |
Day's range | 25.64 - 27.90 |
52-week range | 25.60 - 77.60 |
Volume | |
Avg. volume | 460,644 |
Market cap | 679.962M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.42 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 57.11 |
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
Disc's light sensitivity drug succeeded in a test Monday, but a large placebo response confounded the results. The biotech stock plummeted.